Drug intelligence / Profile preview

hyperpolarized xenon-129 + perfluoropropane

Development stage: Unknown
Lead developer: Polarean Imaging
Modality: Small Molecules
Administration: Inhalation

Overview

A diagnostic imaging combination used for MRI evaluation of lung ventilation and function. Hyperpolarized xenon-129 provides detailed 3D images of ventilated lung airspaces and can quantify lung microstructure and gas exchange, while perfluoropropane (C3F8) serves as an additional inhaled signal source for MR ventilation imaging. The hyperpolarization process significantly enhances the MRI signal of xenon-129 through spin-exchange optical pumping (SEOP), where circularly polarized laser light magnetically aligns xenon nuclei without changing their chemical properties.

Brand names: Xenoview
Other names: HP 129Xe + C3F8hyperpolarized 129Xe + perfluoropropane

Beyond the preview

Go deeper on hyperpolarized xenon-129 + perfluoropropane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyperpolarized xenon-129 + perfluoropropane.

Explore the full profile